公开(公告)号：US20220363640A1

公开(公告)日：2022-11-17

申请号：US17208964

申请日：2021-03-22

Applicant: Janssen BioPharma, Inc.

Inventor： Guangyi WANG ,  Leonid BEIGELMAN ,  Anh TRUONG ,  Carmela NAPOLITANO ,  Daniele ANDREOTTI ,  Haiying HE ,  Karin Ann STEIN

IPC: C07D213/40 ,  C07D409/04 ,  C07D495/14 ,  C07D401/04 ,  C07D413/04 ,  C07D417/04 ,  C07D239/34 ,  C07D471/04 ,  C07D213/65 ,  C07D401/12 ,  C07D491/048 ,  C07D233/64 ,  C07D409/14 ,  C07D417/06 ,  C07D413/12 ,  C07D413/06 ,  C07D401/06 ,  C07D405/12 ,  C07D417/12 ,  C07D207/273 ,  C07D491/052 ,  A61K31/4436 ,  A61K31/4418 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/4365 ,  A61K31/422 ,  A61K31/4196 ,  A61K31/427 ,  A61K31/505 ,  A61K31/437 ,  A61K45/06 ,  A61K31/4355 ,  A61K31/444 ,  A61K31/4709

Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).